| Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects. (NCT02187029) | Pfizer | 2014-07-01 |
| Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk (NCT02702479) | University of Toronto | 2014-06-01 |
| Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment (NCT02128490) | Takeda | 2014-05-01 |
| Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout (NCT02139046) | Takeda | 2014-04-01 |
| Rheumatology Informatics System for Effectiveness (NCT02230943) | American College of Rheumatology | 2014-04-01 |
| Effects of Fasting on Self Efficacy (NCT02113111) | Universität Duisburg-Essen | 2014-04-01 |
| Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients (NCT02063997) | Gilead Sciences | 2014-03-01 |
| Apolipoprotein CIII Reduction Via Colchicine (NCT02083510) | Scripps Translational Science Institute | 2014-02-01 |
| Colchicine Or Naproxen Treatment for ACute gouT (NCT01994226) | Keele University | 2014-01-01 |
| RDEA3170 Monotherapy in Subjects With Gout (NCT01927198) | Ardea Biosciences, Inc. | 2013-08-01 |
| Single and Multiple Dose Study in Japanese Subjects (NCT01872832) | Ardea Biosciences, Inc. | 2013-06-01 |
| NSAID Drug Interaction Study (NCT01884272) | Ardea Biosciences, Inc. | 2013-06-01 |
| Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk (NCT02037321) | John Sievenpiper | 2013-05-01 |
| Arthritis Research UK Gout Treatment Trial - Phase 2 (NCT01477346) | University of Nottingham | 2013-03-01 |
| The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome (NCT01818505) | National Taiwan University Hospital | 2013-03-01 |
| Lesinurad and Febuxostat Combination Extension Study in Gout (NCT01808144) | Ardea Biosciences, Inc. | 2013-03-01 |
| Lesinurad and Allopurinol Combination Extension Study in Gout (NCT01808131) | Ardea Biosciences, Inc. | 2013-02-01 |
| Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial (NCT01881919) | University of Leeds | 2013-02-01 |
| Impact of Unapproved Drug Initiative on Colchicine Use (NCT02000232) | Stanford University | 2013-01-01 |
| Virtual Gout Clinic (NCT02790463) | University of Alabama at Birmingham | 2013-01-01 |
| Purine Metabolism Enzyme SNP to Uric Acid Production (NCT01830725) | Keesler Air Force Base Medical Center | 2012-12-01 |
| Single and Multiple Dose Study in Japanese (NCT01744379) | Ardea Biosciences, Inc. | 2012-12-01 |
| Open-Label Lesinurad Monotherapy Extension Study in Gout (NCT01650246) | Ardea Biosciences, Inc. | 2012-08-01 |
| Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments (NCT01642706) | University Hospital, Montpellier | 2012-07-02 |
| Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease (NCT01608620) | John Sievenpiper | 2012-05-01 |
| Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome (NCT01654276) | University of Texas Southwestern Medical Center | 2012-05-01 |
| Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors (NCT01508702) | Ardea Biosciences, Inc. | 2012-01-01 |
| Combining Lesinurad With Allopurinol in Inadequate Responders (NCT01510158) | Ardea Biosciences, Inc. | 2012-01-01 |
| Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease (NCT04952896) | Peking University Third Hospital | 2012-01-01 |
| Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout (NCT01519687) | Pharmos | 2012-01-01 |
| Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients (NCT05006001) | En Chu Kong Hospital | 2012-01-01 |
| Combining Lesinurad With Allopurinol in Inadequate Responders (NCT01493531) | Ardea Biosciences, Inc. | 2011-12-01 |
| Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (NCT01459796) | Regeneron Pharmaceuticals | 2011-11-01 |
| Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure (NCT01472692) | University of California, San Diego | 2011-10-01 |
| A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency (NCT01407874) | BioCryst Pharmaceuticals | 2011-09-01 |
| Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients (NCT01416402) | Gilead Sciences | 2011-08-01 |
| Allopurinol Outcome Study (NCT01391325) | Ardea Biosciences, Inc. | 2011-07-01 |
| Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients (NCT01399008) | Gilead Sciences | 2011-06-01 |
| Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (NCT01361646) | LG Life Sciences | 2011-06-01 |
| Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout (NCT01336686) | Gilead Sciences | 2011-05-01 |
| Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life (NCT01549210) | Italian Society for Rheumatology | 2011-04-01 |
| Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol (NCT01265264) | BioCryst Pharmaceuticals | 2010-12-01 |
| Hereditary Tubulointerstitial Nephritis (NCT01312727) | Assistance Publique - Hôpitaux de Paris | 2010-11-01 |
| Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management (NCT01151709) | University of Massachusetts, Worcester | 2010-08-01 |
| Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout (NCT01129648) | BioCryst Pharmaceuticals | 2010-05-01 |
| An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. (NCT01112982) | University of South Florida | 2010-05-01 |
| The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study (NCT01701622) | University of Mississippi Medical Center | 2010-01-01 |
| Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia (NCT01052987) | Nuon Therapeutics, Inc. | 2010-01-01 |
| Safety and Efficacy Study of Intramuscular Uricase-PEG 20 (NCT01038947) | EnzymeRx | 2009-12-01 |
| Allopurinol Combination Study (NCT01001338) | Ardea Biosciences, Inc. | 2009-10-01 |
| Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia (NCT00995618) | Nuon Therapeutics, Inc. | 2009-09-01 |
| Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout (NCT00985127) | BioCryst Pharmaceuticals | 2009-09-01 |
| PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) (NCT00958438) | Regeneron Pharmaceuticals | 2009-07-01 |
| Meta-analyses of Fructose and Cardiometabolic Risk (NCT01363791) | John Sievenpiper | 2009-05-01 |
| Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) (NCT00856206) | Regeneron Pharmaceuticals | 2009-03-01 |
| A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) (NCT00819585) | Novartis Pharmaceuticals | 2008-12-01 |
| Uric Acid Study in Healthy Male Volunteers (NCT00738842) | AstraZeneca | 2008-05-01 |
| CLinical Prediction Rule Score in Veterans (NCT01418781) | jasvinder singh | 2008-01-01 |
| Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares (NCT00610363) | Regeneron Pharmaceuticals | 2007-11-01 |
| MPC-004 for the Treatment of an Acute Gout Flare (NCT00506883) | Takeda | 2007-04-01 |
| Efficacy and Safety of Oral Febuxostat in Participants With Gout (NCT00430248) | Takeda | 2007-02-01 |
| Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout (NCT01356498) | Savient Pharmaceuticals | 2006-12-01 |
| Phase III Trial of Febuxostat in Korea Gout Patients (NCT00821392) | SK Chemicals Co., Ltd. | 2006-08-01 |
| Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1) (NCT01685424) | Organon and Co | 2006-06-30 |
| Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout (NCT00325195) | Savient Pharmaceuticals | 2006-05-01 |
| Vegetarian Diet and Chronic Degenerative Diseases (NCT03470584) | Dalin Tzu Chi General Hospital | 2005-03-01 |
| Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout (NCT00111657) | John Sundy | 2004-12-01 |
| A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy (NCT00080210) | Savient Pharmaceuticals | 2004-03-01 |
| Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 (NCT00175019) | Takeda | 2003-07-01 |
| Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. (NCT00174915) | Takeda | 2003-02-01 |
| Validation Study of Physical Measurement of Tophi (NCT00175006) | Takeda | 2002-11-01 |
| Magnetic Resonance Imaging in Subjects With Gouty Tophi (NCT00174954) | Takeda | 2002-03-01 |
| Long-Term Safety of Febuxostat in Subjects With Gout. (NCT00174941) | Takeda | 2001-03-01 |
| Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout (NCT00174967) | Takeda | 2001-01-01 |
| Exploring the Comorbidity Between Mental Disorders and General Medical Conditions (NCT03847753) | University of Aarhus | 2000-01-01 |
| Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout (NCT01310673) | White River Junction Veterans Affairs Medical Center | 1998-01-01 |
| Long-Term Risk of Gout in Living Kidney Donors (NCT07546643) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1992-07-01 |
| Allopurinol in Acute Gout (NCT01775098) | Université de Sherbrooke | |